Oncology Institute (NASDAQ:TOI) Given “Buy” Rating at Needham & Company LLC

Needham & Company LLC reaffirmed their buy rating on shares of Oncology Institute (NASDAQ:TOI) in a report issued on Monday morning,Benzinga reports. They currently have a $5.00 price objective on the stock.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oncology Institute in a research report on Wednesday, January 21st. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $6.50.

Oncology Institute Trading Down 1.8%

Shares of NASDAQ TOI opened at $2.73 on Monday. Oncology Institute has a 12-month low of $0.60 and a 12-month high of $4.88. The stock has a market cap of $268.58 million, a P/E ratio of -4.27 and a beta of 0.14. The business’s fifty day simple moving average is $3.08 and its 200-day simple moving average is $3.41.

Insider Activity

In other news, Director Brad Hively sold 13,333 shares of Oncology Institute stock in a transaction on Monday, December 15th. The shares were sold at an average price of $3.77, for a total transaction of $50,265.41. Following the completion of the sale, the director directly owned 683,721 shares of the company’s stock, valued at approximately $2,577,628.17. The trade was a 1.91% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 8.50% of the company’s stock.

Institutional Trading of Oncology Institute

A number of institutional investors have recently bought and sold shares of the business. Kestra Advisory Services LLC acquired a new position in shares of Oncology Institute during the 4th quarter worth about $31,000. Pekin Hardy Strauss Inc. purchased a new stake in Oncology Institute during the fourth quarter worth approximately $36,000. R Squared Ltd purchased a new stake in Oncology Institute during the fourth quarter worth approximately $41,000. Prelude Capital Management LLC acquired a new position in Oncology Institute in the third quarter valued at approximately $41,000. Finally, ProShare Advisors LLC acquired a new position in Oncology Institute in the second quarter valued at approximately $25,000. 36.86% of the stock is owned by hedge funds and other institutional investors.

Oncology Institute Company Profile

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies.